TELO Telomir Pharmaceuticals, Inc.: יחס שווי פעילות להכנסות

Exclusive anti-aging patents and stringent FDA oversight create significant barriers to entry for Telomir Pharmaceuticals (TELO). This price-to-sales ratio chart visualizes these market positions, where the 0.00 mark serves as the current metric. The absence of commercial products eliminates cash flow predictability, while operating expenses are fully covered by burning through existing reserves.
TELO (Telomir Pharma): פילוחים אנליטיים ודוחות לפי אינדיקטורים

For Telomir Pharmaceuticals (TELO), which is developing innovative telomere restoration methods in gerontology, assessing the business value excluding debt load is critically important. This multiple compares the total enterprise value with the volume of generated sales, allowing for the determination of the real price of every dollar of revenue. By analyzing changes in the EV/Sales multiple, an investor can identify asset undervaluation or systemic risks of the company relative to US industry standards.